ISCOMATRIX() adjuvant is a component of a variety of developmental vaccines. To evaluate the safety profile of ISCOMATRIX() adjuvant we have pooled and analyzed the safety data obtained from a number of vaccine development programs. Overall, the ISCOMATRIX() vaccines from studies included in the analysis were found to be safe and well tolerated, with no vaccine related deaths or Serious Adverse Events. A greater proportion of subjects who received ISCOMATRIX() vaccines experienced local and systemic reactogenicity compared with subjects who received placebo or active comparator, however this reactogenicity was generally mild, self-limiting and of short duration. Similar safety profiles were seen for each of these vaccines. To date, the ISCOMATRIX() vaccines have not been associated with events suggestive of autoimmune or allergic disorders. Specifically, analysis of the ISCOMATRIX() adjuvant adverse event database showed that there was no clustering of symptoms to suggest an allergic or autoimmune syndrome. Additionally, there were no reported autoimmune diagnoses and no events of anaphylaxis per se reported in any of the studies. Generally ISCOMATRIX() adjuvant did not adversely affect safety laboratory parameters and there was no clinically significant difference observed between studies or treatment groups. Studies using ISCOMATRIX() vaccines are ongoing and we continue to proactively analyze the safety of ISCOMATRIX() adjuvant.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4161/hv.6.3.10754 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Enhancement of the immunogenicity of a fusion protein using ISCOMATRIX and PLUSCOM nano-adjuvants as prophylactic vaccine after nasal administration in mice.
Iran J Basic Med Sci
January 2024
Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad Iran.
Objectives: Tuberculosis (TB), a contagious disease caused by (), remains a health problem worldwide and this infection has the highest mortality rate among bacterial infections. Current studies suggest that intranasal administration of new TB vaccines could enhance the immunogenicity of antigens. Hence, we aim to evaluate the protective efficacy and immunogenicity of HspX/EsxS fusion protein of along with ISCOMATRIX and PLUSCOM nano-adjuvants and MPLA through intranasal administration in a mice model.
View Article and Find Full Text PDFMucosal and systemic immunization against tuberculosis by ISCOMATRIX nano adjuvant co-administered with alginate coated chitosan nanoparticles.
Iran J Basic Med Sci
January 2023
Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
Objectives: BCG vaccine has no longer been appreciated to immunize against tuberculosis, worldwide, so novel appropriate adjuvants have been dedicated to improve immune responses. This study aimed to evaluate the immunomodulatory effects of ISCOMATRIX as an adjuvant to stimulate potent humoral and cellular immune responses of the PPE17 loaded alginate coated nanoparticles through subcutaneous and intranasal vaccination.
Materials And Methods: Size, polydispersity index, and morphology of the resulting colloidal particles were explored by dynamic light scattering (DLS).
Prophylactic and therapeutic vaccination protects sperm health from Chlamydia muridarum-induced abnormalities.
Biol Reprod
May 2023
Queensland University of Technology, School of Biomedical Sciences and Centre for Immunology and Infection Control, Faculty of Health, Herston, QLD, Australia.
Chlamydia is the most common bacterial sexually transmitted infection worldwide and it is widely acknowledged that controlling the rampant community transmission of this infection requires vaccine development. In this study, for the first time, we elucidate the long-term response to male mouse chlamydial vaccination with chlamydial major outer membrane protein (MOMP) and ISCOMATRIX (IMX) both prophylactically and in a novel therapeutic setting. Vaccination significantly reduced and, in some cases, cleared chlamydial burden from the prostates, epididymides, and testes, which correlates with high IgG and IgA tires in tissues and serum.
View Article and Find Full Text PDFImmunostimulating Effect of Inactivated Parapoxvirus Ovis on the Serological Response to Equine Influenza Booster Vaccination.
Vaccines (Basel)
December 2022
LABÉO, 14280 Saint-Contest, France.
Equine influenza virus (EIV) is responsible for recurring outbreaks that are detrimental to the equine industry. Vaccination is key for prevention, but the effectiveness and duration of protection provided by existing vaccines is often insufficient. In order to improve vaccine efficacy, we evaluated the benefit of immune stimulation with inactivated Parapoxvirus ovis (iPPVO) on the antibody response induced by a vaccine boost against EIV.
View Article and Find Full Text PDFInfluenza A(H7N9) Pandemic Preparedness: Assessment of the Breadth of Heterologous Antibody Responses to Emerging Viruses from Multiple Pre-Pandemic Vaccines and Population Immunity.
Vaccines (Basel)
November 2022
Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30329, USA.
Influenza A(H7N9) viruses remain as a high pandemic threat. The continued evolution of the A(H7N9) viruses poses major challenges in pandemic preparedness strategies through vaccination. We assessed the breadth of the heterologous neutralizing antibody responses against the 3rd and 5th wave A(H7N9) viruses using the 1st wave vaccine sera from 4 vaccine groups: 1.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!